Quillivant Xr

Attention Deficit Hyperactivity Disorder
Treatment
1 FDA approval
20 Active Studies for Quillivant Xr

What is Quillivant Xr

DexmethylphenidateThe Generic name of this drug
Treatment SummaryDexmethylphenidate is a stimulant used to treat Attention Deficit Hyperactivity Disorder (ADHD). It was introduced in 2002 and is thought to be more effective than other forms of methylphenidate with fewer side effects. Dexmethylphenidate works by increasing the levels of two neurotransmitters, norepinephrine and dopamine, in the brain.
Ritalinis the brand name
image of different drug pills on a surface
Quillivant Xr Overview & Background
Brand Name
Generic Name
First FDA Approval
How many FDA approvals?
Ritalin
Dexmethylphenidate
1955
400

Approved as Treatment by the FDA

Dexmethylphenidate, otherwise known as Ritalin, is approved by the FDA for 1 uses including Attention Deficit Hyperactivity Disorder .
Attention Deficit Hyperactivity Disorder
Helps manage Attention Deficit Hyperactivity Disorder (ADHD)

Effectiveness

How Quillivant Xr Affects PatientsDexmethylphenidate is a form of the drug methylphenidate that is more powerful than the original. It works by blocking the reabsorption of certain chemicals (norepinephrine and dopamine) in the brain.
How Quillivant Xr works in the bodyMethylphenidate helps to regulate dopamine and norepinephrine in the brain, particularly in the thalamus and striatum. Brain scans of people who have taken methylphenidate show changes in blood flow in some parts of the brain. These changes are seen in the striatum, supplementary motor area, and posterior parietal cortex.

When to interrupt dosage

The recommended dosage of Quillivant Xr is contingent upon the diagnosed situation. The amount of dosage varies as indicated by the technique of delivery (e.g. Tablet, film coated, extended release or Capsule, extended release) featured in the table beneath.
Condition
Dosage
Administration
Attention Deficit Hyperactivity Disorder
, 5.0 mg, 10.0 mg, 20.0 mg, 30.0 mg, 40.0 mg, 15.0 mg, 25.0 mg, 35.0 mg, 2.5 mg, 10.0 mg/mL, 5.0 mg/mL, 18.0 mg, 36.0 mg, 27.0 mg, 54.0 mg, 72.0 mg, 85.0 mg, 55.0 mg, 45.0 mg, 70.0 mg, 80.0 mg, 60.0 mg, 100.0 mg, 50.0 mg, 10.4 mg, 6.0 mg/mL, 5.2 mg, 9.0 mg/mL, 30.0 mg/mL, 7.5 mg/mL, 7.8 mg, 1.0 mg/mL, 2.0 mg/mL
, Oral, Capsule, extended release, Capsule, extended release - Oral, Tablet, Tablet - Oral, Capsule - Oral, Capsule, Solution - Oral, Solution, Tablet, chewable, Tablet, extended release, Tablet, extended release - Oral, Tablet, chewable - Oral, Suspension, extended release - Oral, Suspension, extended release, Tablet, Chewable, Extended Release, Tablet, Chewable, Extended Release - Oral, Tablet, film coated, extended release - Oral, Tablet, film coated, extended release

Warnings

Quillivant Xr has nine contraindications, and it should not be taken when encountering the conditions provided in the following table.Quillivant Xr Contraindications
Condition
Risk Level
Notes
Gilles de la Tourette syndrome
Do Not Combine
Tension-Type Headache
Do Not Combine
Agitation
Do Not Combine
Pulse Frequency
Do Not Combine
Tourette Syndrome
Do Not Combine
Tics
Do Not Combine
Generalized Anxiety Disorder
Do Not Combine
Open-angle glaucoma
Do Not Combine
Severe Hypersensitivity Reactions
Do Not Combine
Dexmethylphenidate may interact with Pulse Frequency
There are 20 known major drug interactions with Quillivant Xr.
Common Quillivant Xr Drug Interactions
Drug Name
Risk Level
Description
Azelastine
Major
Dexmethylphenidate may increase the central nervous system depressant (CNS depressant) activities of Azelastine.
Desflurane
Major
Dexmethylphenidate may increase the hypertensive activities of Desflurane.
Diethyl ether
Major
Dexmethylphenidate may increase the hypertensive activities of Diethyl ether.
Enflurane
Major
Dexmethylphenidate may increase the hypertensive activities of Enflurane.
Ethanol
Major
Dexmethylphenidate may increase the central nervous system depressant (CNS depressant) activities of Ethanol.
Quillivant Xr Toxicity & Overdose RiskMethylphenidate affects both genders the same. It is not known if the drug has different effects in different racial groups, children under 6, those with impaired kidney or liver function, pregnant or lactating women, or elderly people. Those with kidney problems do not need a different dosage. Animal studies have shown that pregnant and lactating rats have delayed fetal skeletal ossification and reduced weight gain in male offspring. This means extra caution should be taken when administering this drug, and its benefits and risks should be weighed carefully. Methylphenidate does not seem to increase the risk of cancer, but mice that are sensitive to liver tumors developed
image of a doctor in a lab doing drug, clinical research

Quillivant Xr Novel Uses: Which Conditions Have a Clinical Trial Featuring Quillivant Xr?

77 active trials are currently in progress to ascertain the utility of Quillivant Xr in managing Attention Deficit Hyperactivity Disorder.
Condition
Clinical Trials
Trial Phases
Attention Deficit Hyperactivity Disorder
63 Actively Recruiting
Not Applicable, Phase 3, Phase 4, Phase 1, Phase 2

Quillivant Xr Reviews: What are patients saying about Quillivant Xr?

5Patient Review
2/12/2015
Quillivant Xr for Attention Deficit Disorder with Hyperactivity
We've been using this treatment for my 8 year old daughter since October 2014. Her teacher has reported great results back to us. The only downside is that she seems to have developed a tic where she rubs her hands and face all the time. We're going to lower the dosage a bit to see if it makes any difference.
5Patient Review
3/27/2015
Quillivant Xr for Attention Deficit Disorder with Hyperactivity
This medicine has been a life saver for my 8 year old son. His general attitude and academics have both improved since he started taking it, and his teachers have noticed the difference. We've seen what happens when he misses a dose, and it's clear that this medication is absolutely necessary for him.
5Patient Review
3/26/2015
Quillivant Xr for Attention Deficit Disorder with Hyperactivity
We've tried this medication for our son who has ADD, and it's been great. He takes it once a day and it lasts him through school and homework time. We have noticed that he can get irritable if he misses a dose, though.
5Patient Review
10/10/2017
Quillivant Xr for Attention Deficit Disorder with Hyperactivity
Adderall worked for a year, but we switched to this medicine and it made a world of difference. She's thriving in school now and her test scores have gone up. Plus, she's eating and sleeping better, which makes both her and me much happier. The only downside is that she's become a bit more sensitive, but all things considered I'm very pleased with the switch.
4.3Patient Review
4/7/2016
Quillivant Xr for Attention Deficit Disorder with Hyperactivity
We give our son this medicine every morning before school, and it's helped his behavior a lot. His teachers are really happy with the progress he's made. In the evening, though, he goes back to his old behaviors. We're still trying to figure out what to do about that time of day.
4.3Patient Review
2/28/2016
Quillivant Xr for Attention Deficit Disorder with Hyperactivity
My 8 year old daughter has been on this medicine for over a year and it's made a world of difference in her ability to focus at school and at home. However, she seems to be experiencing some side effects as of late that I wasn't expecting. Has anyone else had this issue?
4.3Patient Review
8/11/2016
Quillivant Xr for Attention Deficit Disorder with Hyperactivity
My daughter, who is 6 and has mild autism, has been taking this medication for about a month. I give her 4 mL every morning before school. It's helped her focus significantly at school; however, she does have decreased appetite and minor difficulty sleeping at night.
3.7Patient Review
5/29/2018
Quillivant Xr for Attention Deficit Disorder with Hyperactivity
Worked great, but now it's been months since it's been in stock. The manufacturer supplied coupons are too complicated and expensive. I suggest finding another drug.
3.7Patient Review
7/10/2021
Quillivant Xr for Attention Deficit Disorder with Hyperactivity
My child started this medication today. I've noticed that she has been talking more, but also curling her lip and licking her lips more often. Is this normal?
3Patient Review
3/25/2021
Quillivant Xr for Attention Deficit Disorder with Hyperactivity
Though this medication has been great for my son in many ways, I have been concerned about his weight loss since he began taking it. He has a hearty appetite and sleeps well, but the weight gain was a big selling point for me when deciding on his treatment and so far we haven't seen those results.
2.3Patient Review
4/21/2022
Quillivant Xr for Attention Deficit Disorder with Hyperactivity
My five year old son has severe ADHD and started taking this medicine on a low-dose about a month ago. He experiences more screen time than usual, gets very quiet, and explains that he feels like he’s going to "blow up" or go crazy. My 11 year old daughter says something very similar about it when she takes the medicine as well.
1Patient Review
8/2/2015
Quillivant Xr for Attention Deficit Disorder with Hyperactivity
My son started taking this drug a month ago and it has been an absolute nightmare. The insomnia is the worst part - he doesn't sleep for more than an hour or two at a time, if at all. And during the day he's ravenous, eating everything in sight. This medicine was great at first but the side effects are just not worth it anymore.
image of drug pills surrounding a glass of water symbolizing drug consumption

Patient Q&A Section about quillivant xr

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

How long does it take Quillivant XR to work?

"After taking Quillivant XR, it will start working within 45 minutes and will continue to work for 12 hours. This means that if it is taken at 7am, it will remain effective until evening."

Answered by AI

Has Quillivant XR been discontinued?

"Amber Corn, a mother in Indiana, said she was told by her pharmacy that it could not order the drug because it was “discontinued.” However, according to the FDA's database on drug shortages and discontinuations, both Quillivant XR and Quillichew ER are “currently in shortage”. Tris Pharma says it is producing and releasing ...Mar 31, 2022"

Answered by AI

Is Quillivant XR the same as Ritalin?

"Although Quillivant XR has not been studied in children under the age of 6, it may improve focus and decrease impulsivity and hyperactive behavior in children. Quillivant XR is a federally controlled substance (CII) because it can be abused or lead to dependence, according to the FDA."

Answered by AI

What does Quillivant XR do?

"This medication is used to treat attention deficit hyperactivity disorder - ADHD. It works by changing the levels of certain natural substances in the brain. Methylphenidate belongs to a class of drugs known as stimulants."

Answered by AI

Clinical Trials for Quillivant Xr

Image of St. Jude Children's Research Hospital in Memphis, United States.

Methylphenidate for Sickle Cell Disease

8 - 17
All Sexes
Memphis, TN
The purpose of this study is to determine if patients with sickle cell disease (SCD) can consistently take a drug called Methylphenidate (MPH) daily, once a day for 4 weeks to help with any thinking, attention or schoolwork problems and if they have any side effects. The study will assess any thinking or attention problems participants may have both before taking this drug and after. Additionally, the study will assess the decision-making process of the caregiver that may influence using this drug or not. Primary Objective: • Assess the feasibility, acceptability, and adherence to MPH treatment in children with SCD and EF deficits. Secondary Objective: • Evaluate neurobehavioral and safety outcomes following MPH treatment. Exploratory Objective: • Evaluate decision-making and determinants influencing methylphenidate utilization among parents.
Phase 1
Recruiting
St. Jude Children's Research HospitalAndrew Heitzer, PhD
Image of The University of Iowa in Iowa City, United States.

fMRI for Cognitive Flexibility

18 - 35
All Sexes
Iowa City, IA
The goal of this basic experimental research study is to examine how the human thalamus supports flexible thinking and behavior. Specifically, the research aims to elucidate how the mediodorsal (MD) thalamus encodes and updates "context"-the mental framework that determines which rules or actions are relevant in a given situation. This work may contribute to understanding why certain psychiatric conditions, such as schizophrenia and ADHD, involve difficulties with cognitive flexibility and control. The primary research questions are: Does the MD thalamus represent the context that organizes how working memory guides task selection? Does the MD thalamus signal when context needs to be updated after a change in task demands? Do these thalamic representations support generalization to new situations or rules? Participants will complete cognitive tasks while undergoing high-resolution brain imaging using 7-Tesla MRI. The investigators will combine behavioral data, computational modeling, and advanced neuroimaging analyses to examine how the thalamus interacts with the cortex during flexible decision-making.
Waitlist Available
Has No Placebo
The University of Iowa
Image of UCSF Nancy Friend Pritzker Psychiatry Building in San Francisco, United States.

Trigeminal Nerve Stimulation for ADHD in Children with Autism

7 - 14
All Sexes
San Francisco, CA
The goal of this clinical trial is to learn if external trigeminal nerve stimulation (eTNS) works to treat ADHD symptoms in children on the autism spectrum (ASD). It will also learn about the efficacy and tolerability of the eTNS device. The main questions it aims to answer are: * Does eTNS reduce ADHD symptoms? * Does eTNS improve core and associated features of ASD? Participation spans 8-12 weeks and includes: * 4-5 in-person visits * 4 brief virtual check-ins * Nightly use of the eTNS device with a small sticky patch applied to child's forehead * Randomized assignment (those who start with the sham device may try the active device later)
Recruiting
Device
UCSF Nancy Friend Pritzker Psychiatry Building
Have you considered Quillivant Xr clinical trials? We made a collection of clinical trials featuring Quillivant Xr, we think they might fit your search criteria.Go to Trials
Image of Hoskinson Health and Wellness Clinic in Gillette, United States.

Biofeedback and Lifestyle Interventions for ADHD

7 - 18
All Sexes
Gillette, WY
The Pediatric Healing Minds II intervention includes a biofeedback component, breathing practices nutrition and exercise counseling. Biofeedback is a type of mind-body technique used to control body functions such as heart, lung and muscle responses. Biofeedback uses therapeutic techniques that aim to help study participants gain more awareness and control over certain physiological functions in their bodies. It involves the use of electronic monitoring equipment to provide real-time information about physiological processes such as heart rate, HRV, coherence and muscle tension. This information is then provided back to the study participant, allowing them to learn how to consciously regulate these processes. During the sessions parents are expected to attend and participate. Study participants and parents will have access to a video that provides instructions for placement of the Heart Math single small ear lobe or finger sensor. Breathing Practices include alternate nostril, qi gong and other breathing practices. Nutrition counseling includes nutrition supplementation to correct deficiencies, dietary education and an age-and gender-specific diet prescription based on the Mediterranean Diet. Exercise counseling includes developmentally appropriate guidelines for cardiopulmonary, strength and flexibility activities based on guidelines from the American College of Sports Medicine (ACSM) and the American Academy of Pediatrics (AAP). The objective of this research proposal is to examine the combined effects of an integrative approach including biofeedback, breathing practices, nutrition and exercise counseling intervention (Healing Minds II), on symptoms and severity of ADHD, impulsivity and attention (e.g., QB continuous performance test) in youth 7-18 years of age. The investigators hypothesize that ADHD symptoms and severity, impulsivity and attention will be significantly improved and coherence increased after participation in the 6-month intervention. The investigators also propose that ADHD severity in those patients with prescribed medication but poorly-controlled ADHD will demonstrate the greatest improvement compared to those not prescribed medication and those who have well-controlled ADHD.
Waitlist Available
Has No Placebo
Hoskinson Health and Wellness ClinicInara McMaster, MDHoskinson Health and Wellness Clinic
Image of Louisiana State University in Baton Rouge, United States.

Virtual Reality for ADHD

18 - 25
All Sexes
Baton Rouge, LA
The goal of this larger parallel group randomized trial is to test the impact of a virtual reality program for improving the ability of emerging adults (age 18-25) with attention deficit hyperactivity disorder (ADHD) to stay focused while completing homework and studying. This study compares the impact of using a virtual reality headset to using a virtual reality headset while also receiving feedback about levels of focus to a control group. The main question is whether participants demonstrate significantly improved concentration while completing homework and studying in virtual reality and whether they enjoy and prefer working in a virtual reality environment. Concentration is measured both through participant report and also using keyboard and mouse click data to assess work productivity objectively.
Phase 4
Waitlist Available
Louisiana State University (+1 Sites)Joshua M Langberg, PhD
Image of Duke University in Durham, United States.

Organizational Skills Training vs Mindfulness for ADHD

13 - 17
All Sexes
Durham, NC
This randomized control trial comparing Organizational Skills Training (OST) and Mindfulness-Based Intervention (MBI) among adolescents with a pre-existing ADHD diagnosis presenting to the Duke ADHD Program. Both treatments are eight 90 minute sessions. The research component will involve a pre-treatment assessment and post-treatment assessment. Both assessments will involve adolescents and one caregiver to complete questionnaires over REDCap. Rating scales will include ADHD symptom severity (Conners 3: self and parent report), functional impairment (IRS: self and parent report), executive functioning (BRIEF-2: parent report), emotion dysregulation (DERS: self and parent report), trait mindfulness (FFMQ: self report), organizational skills (BRIEF-2: parent report), treatment satisfaction (self report and parent report) and credibility (self report and parent report). Post-treatment assessments for feasibility will include attendance (measured over the course of treatment) and homework completion rates on a scale of 1 to 5 in which 5 indicates higher homework completion. We will also assess acceptability via individual items on a Likert scale (self report): overall satisfaction, how much was learned about ADHD, usefulness of information learned, content relevance to individual experience, comprehension of strategies, confidence about using strategies, likelihood of using strategies, helpfulness to share with the group, benefits from hearing from other group members, willingness to recommend the same treatment to others, and whether or not treatment was beneficial.
Recruiting
Has No Placebo
Duke UniversityJohn Mitchell, PhD
Have you considered Quillivant Xr clinical trials? We made a collection of clinical trials featuring Quillivant Xr, we think they might fit your search criteria.Go to Trials
Image of Montana State University in Bozeman, United States.

Speech-Gesture Combinations for Autism

Any Age
All Sexes
Bozeman, MT
This research study investigates how hand gestures can support language comprehension and communication skills of hearing speaking, non-speaking, and/or minimally verbal individuals with Autism Spectrum Disorders (ASD), who are especially disadvantaged by the lack of accessible services in their rural communities. Individuals with other cognitive profiles, including Developmental Language Disorder (DLD), ADHD, Dyslexia, and others are welcome too. The study uses methods of eye tracking and recording of brain activity to understand how hand gestures adapted from signs from American Sign Language, such as \[cry\], can promote successful understanding of words like "cry". The overarching goal is to help families effectively utilize gestures to support communication with their children.
Recruiting
Has No Placebo
Montana State University
Image of University of Pennsylvania in Philadelphia, United States.

Measurement Feedback App for Autism Spectrum Disorder

18+
All Sexes
Philadelphia, PA
The goal of this clinical trial is to test whether a smartphone-based data collection and feedback application ("Footsteps") improves the quality of behavioral data collected by one-to-one aides and leads to better youth mental health outcomes in school-aged youth (ages 4-17) who receive one-to-one support in schools. The main questions it aims to answer are: 1. Does the Footsteps app improve aides' data collection quality (i.e., consistency, timeliness, and completeness)? 2. Does Footsteps use lead to improved youth behavioral health outcomes (e.g., SDQ, YTP, GAS scores)? 3. Does Footsteps improve communication and supervision processes between aides and clinical supervisors? Researchers will compare aides using Footsteps to those using a "data collection only" control app to see if Footsteps leads to higher quality data collection, enhanced supervisory communication, and better youth outcomes. Participants will: * Use either Footsteps or a control app to record de-identified data on one client's behaviors and skills over 12 weeks * Complete biweekly online surveys about data collection experiences, youth progress, and aide-supervisor communication * Participate in a virtual intake and post-trial meeting * (For a subset) Participate in a 30-45 minute qualitative interview about their experience using the app
Waitlist Available
Has No Placebo
University of PennsylvaniaHeather J Nuske, PhD
Image of Boston Children's Hospital Laboratories of Cognitive Neuroscience in Brookline, United States.

Guided Deep Breathing for ADHD

7 - 11
All Sexes
Brookline, MA
Attention-deficit/hyperactivity disorder (ADHD) affects approximately 11% of children and adolescents in the United States. Individuals with ADHD experience substantial impairments and burdens across multiple areas of daily living, including peer difficulties, academic difficulties, poor job outcomes, high rates of co-occurring disorders, and large financial costs. Although there are many well-established, evidence-based treatments for ADHD, many children continue to experience significant impairment and elevated ADHD symptoms even with prolonged treatment. Further, there are several limitations to existing treatment approaches, including medication side effects, difficulty accessing behavioral treatments, and high out-of-pocket costs for behavioral treatments. Thus, there is a crucial need to identify low cost, low burden, alternative or additive intervention approaches for pediatric ADHD. In the current pilot study, we aim to evaluate responses in behavioral and brain-based markers of attention to a mindfulness-based intervention. Mindfulness-based interventions (MBIs), including deep breathing, have received considerable research attention regarding their benefits for ADHD symptoms. Deep breathing is a strong candidate as a supplementary MBI intervention for children with ADHD due to its simplistic and easy-to-implement nature. Studies examining the effects of deep breathing on physiological arousal and ADHD symptoms in children have yielded promising results. Children will be led through a brief deep breathing intervention using a novel tool designed to optimize child engagement in deep breathing. This tool, Domi, is designed to be held in the child's hands and uses a series of haptic vibrations to provide real-time deep breathing pacing guidance. We predict that following a brief deep breathing practice, children with ADHD will demonstrate improved sustained attention, reaction time consistency, and inhibitory control. These areas of attention and behavioral functioning will be assessed using computer tasks and measures of brain activity. We plan to use the results of this study to strengthen a future application for grant funding to run a similar trial with many more children. We believe that the results of this and future studies will improve the lives of children with ADHD and their families.
Waitlist Available
Has No Placebo
Boston Children's Hospital Laboratories of Cognitive Neuroscience
Image of UPMC Magee-Womens Hospital in Pittsburgh, United States.

MomMA Intervention for ADHD

18+
Female
Pittsburgh, PA
The goal of this study is to test a behavioral program for pregnant individuals with ADHD. This behavioral program focuses on skills for managing ADHD and related symptoms in pregnancy and postpartum. This pilot effectiveness-implementation trial aims to (1) preliminarily evaluate the MomMA behavioral intervention compared to treatment as usual (TAU) on clinical outcomes and (2) evaluate implementation outcomes, including feasibility and acceptability of clinic screening within existing OB workflows; assessment and intervention protocols; provider training/fidelity to manual; and all other study protocols from the perspective of real-world providers and participants.
Waitlist Available
Has No Placebo
UPMC Magee-Womens HospitalHeather M Joseph, DO Assistant Professor of Psychiatry and Pediatrics
Have you considered Quillivant Xr clinical trials? We made a collection of clinical trials featuring Quillivant Xr, we think they might fit your search criteria.Go to Trials
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security